Outcomes of concomitant bedaquiline and delamanid in patients with multidrug-resistant TB

Concomitant treatment with bedaquiline and delamanid (Bdq-Dlm) was determined to be safe and effective and did not increase the risk for cardiotoxicity in patients with multidrug- and rifampicin-resistant (MDR/RR) tuberculosis (TB) infection, according to results of a study published in Clinical Infectious Diseases.